Arrowhead Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1989-01-01

Employees: 525

Market Cap: $2.9B

Website: http://www.arrowheadpharma.com

Introduction: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Ste...

Clinical Trials

Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus

Phase 1

Not yet recruiting

Conditions: Obesity

Interventions: Drug: ARO-INHBE
Drug: Placebo
Drug: Tirzepatide

First Posted Date: 2024-11-22

Last Posted Date: 2024-11-22

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 78

Registration Number: NCT06700538

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Phase 1

Recruiting

Conditions: Spinocerebellar Ataxia Type 2

Interventions: Drug: ARO-ATXN2 Injection
Drug: Placebo

First Posted Date: 2024-11-04

Last Posted Date: 2024-12-06

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06672445

Locations: 🇳🇿
Research Site, Christchurch, New Zealand

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Plozasiran Injection
Drug: Placebo

First Posted Date: 2024-04-04

Last Posted Date: 2024-11-28

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT06347016

Locations: 🇺🇸
RNA America Health Sciences, Sugar Hill, Georgia, United States
🇺🇸
Midwest Cardiovascular Research and Education Foundation, Elkhart, Indiana, United States
🇺🇸
Ascension St. Vincent Heart Center, Indianapolis, Indiana, United States

and more 77 locations

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Severe Hypertriglyceridemia

Interventions: Drug: Plozasiran Injection
Drug: Placebo

First Posted Date: 2024-04-04

Last Posted Date: 2024-11-25

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 405

Registration Number: NCT06347003

Locations: 🇨🇦
Nova Scotia Health Authority, Halifax, Canada
🇨🇳
Yuncheng Central Hospital, Yuncheng, Shanxi, China
🇺🇸
East Coast Institute for Research, LLC, Lake City, Florida, United States

and more 65 locations

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Phase 3

Recruiting

Conditions: Hypertriglyceridemia

Interventions: Drug: Placebo
Drug: Plozasiran Injection

First Posted Date: 2024-04-04

Last Posted Date: 2024-11-27

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 1328

Registration Number: NCT06347133

Locations: 🇺🇸
IMC Diagnostic and Medical Clinic, LLC, Mobile, Alabama, United States
🇺🇸
East Coast Institute for Research, LLC, Lake City, Florida, United States
🇺🇸
Northwell Health Physician Partners at Peconic, Riverhead, New York, United States

and more 100 locations

Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease

Phase 1

Recruiting

Conditions: IgA Nephropathy

Interventions: Drug: ARO-CFB
Drug: Placebo

First Posted Date: 2024-01-17

Last Posted Date: 2024-04-24

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 66

Registration Number: NCT06209177

Locations: 🇳🇿
New Zealand Clinical Research OPCO Ltd, Auckland, New Zealand

Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy

Phase 1

Recruiting

Conditions: Myotonic Dystrophy 1

Interventions: Drug: ARO-DM1 for Injection
Drug: Placebo

First Posted Date: 2023-11-18

Last Posted Date: 2024-10-01

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT06138743

Locations: 🇳🇿
Research Site, Christchurch, New Zealand

Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Phase 1

Recruiting

Conditions: Facio-Scapulo-Humeral Dystrophy

Interventions: Drug: ARO-DUX4 for Injection
Drug: Placebo

First Posted Date: 2023-11-15

Last Posted Date: 2024-10-24

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT06131983

Locations: 🇹🇭
Research Site, Bangkok, Thailand

Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Phase 1

Withdrawn

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: ARO-SOD1 Injection

First Posted Date: 2023-07-18

Last Posted Date: 2024-04-17

Lead Sponsor: Arrowhead Pharmaceuticals

Registration Number: NCT05949294

Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Phase 1

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: ARO-MMP7 Inhalation Solution
Drug: Placebo

First Posted Date: 2022-09-13

Last Posted Date: 2024-12-20

Lead Sponsor: Arrowhead Pharmaceuticals

Target Recruit Count: 97

Registration Number: NCT05537025

Locations: 🇮🇹
AOUC Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
🇩🇰
Rigshospitalet- University Hosptial of Copenhagen, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark

and more 10 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy